VisualDx Awarded Grant to Advance Global Health and Diagnostic Accuracy in Underserved Regions
The grant from the Bill & Melinda Gates Foundation will support the deployment of decision…
Year: 2023
Independent Survey of More Than 1,000 CXO Respondents Across UK, Ireland, Nordics and the GCC Show Continued Plan for Digital Transformation Investments in 2023
CXOs balance need for new investments in digital technologies to drive innovation and interoperability while…
WatchGuard names Simon Yeo Senior Vice President of Operations
Industry veteran and former Barracuda executive to lead company’s IT systems and infrastructure, security, and…
Castellum, Inc. Announces Signing of Non-Binding LOI for East Coast Government Contractor
Castellum, Inc. Announces Signing of Non-Binding LOI for East Coast Government Contractor Castellum, Inc. (NYSE-American:…
Castellum, Inc. Announces Signing of Non-Binding LOI for East Coast Government Contractor
Castellum, Inc. Announces Signing of Non-Binding LOI for East Coast Government Contractor Castellum, Inc. (NYSE-American:…
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB:…
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB:…
ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas
Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of…
ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas
Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of…
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Thursday, January 19th at 12:00 PM ET DURHAM, N.C., Jan. 18,…
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Thursday, January 19th at 12:00 PM ET DURHAM, N.C., Jan. 18,…
Hinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical Development
Barry Selick, Ph.D., successful biopharmaceutical scientist, senior executive and entrepreneur, appointed Chief Executive Officer Carin…
Hinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical Development
Barry Selick, Ph.D., successful biopharmaceutical scientist, senior executive and entrepreneur, appointed Chief Executive Officer Carin…
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis
Global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in Europe SAN DIEGO, Jan….
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis
Global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in Europe SAN DIEGO, Jan….
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System
Wound care professionals across multiple specialties to support strategic alignment of patient, payor, and provider…
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System
Wound care professionals across multiple specialties to support strategic alignment of patient, payor, and provider…
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
Preliminary full year revenue for 2022 of approximately $ 2.7 million is within most recent…
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
Preliminary full year revenue for 2022 of approximately $ 2.7 million is within most recent…
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
The Company has already secured approvals from Ethics Committee and Israeli Ministry of Health for the Company’s study with its proprietary SCI-210 treatment…